AMGN News
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER IN THE CARDIOVASCULAR RISK CONTINUUMPR NewswireTHOUSAND OAKS, Calif., Nov. 9, 2026 Independent VESALIUS-CV...
PR Newswire
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER IN THE CARDIOVASCULAR RISK CONTINUUMPR NewswireTHOUSAND OAKS, Calif., Nov. 9, 2026 Independent VESALIUS-CV...
PR Newswire
Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays ElevatedPR NewswireVANCOUVER, BC, Nov. 9, 2026 VANCOUVER, BC, Nov. 9, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Wall Street...
PR Newswire
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks
Key PointsAmgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases...
Nasdaq News: Markets
REPATHA LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY REPATHA LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDYPR NewswireTHOUSAND OAKS, Calif., Nov. 5, 2026 Findings Represent Largest and Most Rigorous Head-to-Head...
PR Newswire
Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings StoryPR NewswireNEW YORK, Nov. 4, 2026 NEW YORK, Nov. 4, 2026 /PRNewswire/ --Fly on Wall Street News Commentary- Wall Street's major indexes...
PR Newswire
Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8% Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8%PR NewswireVANCOUVER, BC, Nov. 4, 2026 VANCOUVER, BC, Nov. 4, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Wall Street roared higher this...
PR Newswire
Amgen raises its 2026 outlook after Q3 earnings and revenue beat estimates, as IMDELLTRA advances and MariTide offers potential long-term growth opportunities.
Zacks
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 2.06% on an annualized basis producing an average annual return of 14.83%. Currently, Amgen has a market capitalization of $249.37 billion.read more...
Benzinga
Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.
Zacks